Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Holdings Increased by M&T Bank Corp

M&T Bank Corp boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 48.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,719 shares of the medical equipment provider’s stock after buying an additional 8,709 shares during the quarter. M&T Bank Corp’s holdings in Zimmer Biomet were worth $2,884,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. American Century Companies Inc. raised its position in shares of Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after purchasing an additional 722,041 shares during the period. Equity Investment Corp purchased a new stake in Zimmer Biomet during the third quarter valued at about $70,104,000. Hotchkis & Wiley Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 49.1% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after buying an additional 577,320 shares during the period. Magnetar Financial LLC increased its position in shares of Zimmer Biomet by 58.7% in the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock worth $142,203,000 after acquiring an additional 484,816 shares in the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after acquiring an additional 411,163 shares during the period. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several research analyst reports. Oppenheimer lowered their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Barclays dropped their price target on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday. Royal Bank of Canada lifted their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Wells Fargo & Company increased their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, BTIG Research dropped their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $122.83.

Zimmer Biomet Price Performance

NYSE ZBH opened at $106.74 on Friday. The stock has a 50-day simple moving average of $107.69 and a 200 day simple moving average of $108.75. Zimmer Biomet Holdings, Inc. has a twelve month low of $101.47 and a twelve month high of $133.90. The stock has a market capitalization of $21.25 billion, a PE ratio of 20.29, a P/E/G ratio of 1.96 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period in the previous year, the company earned $1.65 earnings per share. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.